Clinical Trials
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2205
ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Status Notes
This study is open to patient accrual effective 3/16/23 at 12 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
03-16-2023
ClinicalTrials.gov Registry Number
05642611
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Status Notes
March 6, 2023: S2302 is open to accural.
Research Committee(s)
Lung Cancer
Activated
03-06-2023
ClinicalTrials.gov Registry Number
05633602
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
EAY191-S3
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors
Status Notes
This study is open to participant enrollment effective 12pm PT on 3/6/2023.
Research Committee(s)
comboMATCH
Immunomolecular Therapeutics
Activated
03-06-2023
ClinicalTrials.gov Registry Number
05554380
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Research Committee(s)
Lymphoma
Activated
02-23-2023
ClinicalTrials.gov Registry Number
05633615
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2010
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Status Notes
This study is open to participant accrual, effective January 17, 2023, at 12:00 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
01-17-2023
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
S2101
Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
Status Notes
Activation: Effective October 14, 2022 at 12:00 PM Pacific Time
Research Committee(s)
iMATCH
Head and Neck Cancer
Melanoma
Early Therapeutics & Rare Cancers
Activated
10-14-2022
ClinicalTrials.gov Registry Number
NCT 05136196